This study enrolls patients with newly diagnosed differentiated thyroid cancer (papillary thyroid cancer or follicular thyroid cancer) that has spread to the lungs and has a genetic mutation called and RET fusion.
The Grupp Lab develops new targeted cancer treatments and cell-based immunotherapies for leukemia and solid tumors, and aims to create advanced, less toxic treatments for children with high-risk cancers.
This study enrolls patients that have been diagnosed with SMARCB1 or SMARCB4 deficient cancer that has either come back (“relapsed”) or does not respond to therapy (“is refractory”) or have been newly diagnosed with a SMARCB1 or SMARCB4 deficient cancer that has no known standard treatment.
